<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218292</url>
  </required_header>
  <id_info>
    <org_study_id>PMCF 24October2019</org_study_id>
    <nct_id>NCT04218292</nct_id>
  </id_info>
  <brief_title>Dr. Amplatz Micro Plug - Post Market Clinical Follow-up (PMCF) Plan</brief_title>
  <official_title>Dr. Amplatz Micro Plug - Post Market Clinical Follow-up (PMCF) Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KA Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KA Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, post market clinical follow-up (PMCF) intended to evaluate the
      residual risks of the Dr. Amplatz Micro Plug which is intended for use during arterial
      embolization of the peripheral vasculature. This PMCF will collect data pertaining to any
      adverse events as well as the identification of any unanticipated risks up to the first 12
      months following device implant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious device-related and procedure-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of serious device-related and procedure-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of successful delivery of the device</measure>
    <time_frame>1 day</time_frame>
    <description>Rate of successful delivery of the Dr. Amplatz Micro Plug to the intended position.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Trauma Injury</condition>
  <condition>Bleeding</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dr. Amplatz Micro Plug</intervention_name>
    <description>The Dr. Amplatz Micro Plug is indicated for arterial embolization in the peripheral vasculature.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring routine standard of care for peripheral embolization. Some of the
        patients will be liver cancer patients undergoing palliative treatment with SIRT who have a
        life expectancy that may be less than 12 months. Other patients may be treated for trauma
        or bleeding.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is scheduled for arterial embolization in the peripheral vasculature.

          -  Subject is greater than 18 years of age

        Exclusion Criteria:

          -  Subject is unable to give informed consent

          -  Subject is pregnant or breastfeeding

          -  Subject has allergy to nickel

          -  Patient requires neurologic or cardiac use of an occlusion device, contrary to the Dr.
             Amplatz Micro Plug Instructions For Use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Pech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Magdeburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Oslund</last_name>
    <phone>651-256-0802</phone>
    <email>joslund@ka-medical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maceij Pech, MD</last_name>
      <phone>+49 391 67 13030</phone>
      <email>Maciej.Pech@med.ovgu.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>pseudonymized data will be compiled in a final report that will be submitted to the European Ethics Committees and the Notified Body for the approval to market in Europe.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be provided when the PMCF ends.</ipd_time_frame>
    <ipd_access_criteria>The final report is a confidential document that is provided to the Ethics Committees and the notified body.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

